Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - follitropin alfa, quantity: 300 iu - injection, solution - excipient ingredients: polysorbate 20; water for injections; sodium hydroxide; benzalkonium chloride; benzyl alcohol; mannitol; methionine; monobasic sodium phosphate dihydrate - 1. the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated.,2. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies.,3. ovaleap is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - follitropin alfa, quantity: 900 iu - injection, solution - excipient ingredients: polysorbate 20; benzalkonium chloride; sodium hydroxide; water for injections; benzyl alcohol; mannitol; methionine; monobasic sodium phosphate dihydrate - 1. the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated.,2. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies.,3. ovaleap is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - follitropin alfa, quantity: 450 iu - injection, solution - excipient ingredients: benzalkonium chloride; benzyl alcohol; mannitol; water for injections; methionine; polysorbate 20; sodium hydroxide; monobasic sodium phosphate dihydrate - 1. the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated.,2. for controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies.,3. ovaleap is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

United States - English - NLM (National Library of Medicine)

organon usa inc. - follitropin (unii: 076whw89tw) (follitropin - unii:076whw89tw) - follitropin 75 [iu] in 0.5 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - lutropin alfa, quantity: 75 iu - injection, powder for - excipient ingredients: methionine; sodium hydroxide; phosphoric acid; sucrose; polysorbate 20; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate - luveris in association with a recombinant follicle stimulating hormone (fsh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh of less than 1.2 iu/l.

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - follitropin (unii: 076whw89tw) (follitropin - unii:076whw89tw) - follitropin 75 [iu] in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - in the female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). in the male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - in the female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). in the male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - in the female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). in the male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.